S&P 500   4,269.46 (-0.44%)
DOW   33,318.87 (-0.34%)
QQQ   358.70 (-0.71%)
AAPL   172.40 (-0.78%)
MSFT   319.50 (-0.71%)
META   305.47 (-0.44%)
GOOGL   133.30 (-0.65%)
AMZN   128.40 (-0.82%)
TSLA   248.38 (-1.28%)
NVDA   446.75 (-0.24%)
NIO   8.53 (-2.96%)
BABA   84.59 (-2.24%)
AMD   102.05 (-1.18%)
T   14.68 (+0.07%)
F   12.22 (-0.73%)
MU   67.17 (-1.16%)
CGC   0.72 (-2.04%)
GE   108.00 (-0.73%)
DIS   81.05 (-0.76%)
AMC   8.07 (-0.98%)
PFE   33.78 (-0.47%)
PYPL   58.00 (-0.96%)
NFLX   377.50 (-0.74%)
S&P 500   4,269.46 (-0.44%)
DOW   33,318.87 (-0.34%)
QQQ   358.70 (-0.71%)
AAPL   172.40 (-0.78%)
MSFT   319.50 (-0.71%)
META   305.47 (-0.44%)
GOOGL   133.30 (-0.65%)
AMZN   128.40 (-0.82%)
TSLA   248.38 (-1.28%)
NVDA   446.75 (-0.24%)
NIO   8.53 (-2.96%)
BABA   84.59 (-2.24%)
AMD   102.05 (-1.18%)
T   14.68 (+0.07%)
F   12.22 (-0.73%)
MU   67.17 (-1.16%)
CGC   0.72 (-2.04%)
GE   108.00 (-0.73%)
DIS   81.05 (-0.76%)
AMC   8.07 (-0.98%)
PFE   33.78 (-0.47%)
PYPL   58.00 (-0.96%)
NFLX   377.50 (-0.74%)
S&P 500   4,269.46 (-0.44%)
DOW   33,318.87 (-0.34%)
QQQ   358.70 (-0.71%)
AAPL   172.40 (-0.78%)
MSFT   319.50 (-0.71%)
META   305.47 (-0.44%)
GOOGL   133.30 (-0.65%)
AMZN   128.40 (-0.82%)
TSLA   248.38 (-1.28%)
NVDA   446.75 (-0.24%)
NIO   8.53 (-2.96%)
BABA   84.59 (-2.24%)
AMD   102.05 (-1.18%)
T   14.68 (+0.07%)
F   12.22 (-0.73%)
MU   67.17 (-1.16%)
CGC   0.72 (-2.04%)
GE   108.00 (-0.73%)
DIS   81.05 (-0.76%)
AMC   8.07 (-0.98%)
PFE   33.78 (-0.47%)
PYPL   58.00 (-0.96%)
NFLX   377.50 (-0.74%)
S&P 500   4,269.46 (-0.44%)
DOW   33,318.87 (-0.34%)
QQQ   358.70 (-0.71%)
AAPL   172.40 (-0.78%)
MSFT   319.50 (-0.71%)
META   305.47 (-0.44%)
GOOGL   133.30 (-0.65%)
AMZN   128.40 (-0.82%)
TSLA   248.38 (-1.28%)
NVDA   446.75 (-0.24%)
NIO   8.53 (-2.96%)
BABA   84.59 (-2.24%)
AMD   102.05 (-1.18%)
T   14.68 (+0.07%)
F   12.22 (-0.73%)
MU   67.17 (-1.16%)
CGC   0.72 (-2.04%)
GE   108.00 (-0.73%)
DIS   81.05 (-0.76%)
AMC   8.07 (-0.98%)
PFE   33.78 (-0.47%)
PYPL   58.00 (-0.96%)
NFLX   377.50 (-0.74%)
NASDAQ:AXSM

Axsome Therapeutics (AXSM) Stock Forecast, Price & News

$66.85
-3.04 (-4.35%)
(As of 10/2/2023 ET)
Compare
Today's Range
$66.64
▼
$70.00
50-Day Range
$66.85
▼
$82.21
52-Week Range
$38.87
▼
$91.29
Volume
1.04 million shs
Average Volume
633,929 shs
Market Capitalization
$3.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$104.45
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Axsome Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
56.3% Upside
$104.45 Price Target
Short Interest
Bearish
17.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.35mentions of Axsome Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$828,293 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.04) to ($2.83) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

79th out of 975 stocks

Pharmaceutical Preparations Industry

19th out of 454 stocks

See Top Rated MarketRank™ Stocks Here

AXSM stock logo

About Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

AXSM Price History

AXSM Stock News Headlines

October 3, 2023 | markets.businessinsider.com
Maintaining Buy Rating for Axsome Therapeutics: Steady Auvelity Sales and Anticipated Q3 Performance Insights
October 2, 2023 | finance.yahoo.com
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
October 3, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
October 1, 2023 | americanbankingnews.com
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 3.7%
September 28, 2023 | businesswire.com
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
September 28, 2023 | americanbankingnews.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Recommendation of "Moderate Buy" from Analysts
September 26, 2023 | americanbankingnews.com
Axsome Therapeutics (NASDAQ:AXSM) Receives Buy Rating from Mizuho
September 21, 2023 | finance.yahoo.com
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
October 3, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
September 19, 2023 | finance.yahoo.com
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Earnings Haven't Escaped The Attention Of Investors
September 10, 2023 | realmoney.thestreet.com
This Promising Biotech Is Just Right for a Covered-Call Play
September 7, 2023 | finance.yahoo.com
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
September 5, 2023 | finance.yahoo.com
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
September 1, 2023 | seekingalpha.com
Axsome: Beyond The Numbers - Q2 Earnings Sparkle And A Pipeline Full Of Promise
August 22, 2023 | nasdaq.com
Cantor Fitzgerald Reiterates Axsome Therapeutics (AXSM) Overweight Recommendation
August 16, 2023 | msn.com
BofA upgrades Axsome to neutral, cites improved outlook for MDD drug
August 12, 2023 | msn.com
Mizuho Maintains Axsome Therapeutics (AXSM) Buy Recommendation
August 9, 2023 | finance.yahoo.com
Axsome Therapeutics Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
August 9, 2023 | msn.com
Piper Sandler Upgrades Axsome Therapeutics (AXSM)
August 9, 2023 | msn.com
B of A Securities Upgrades Axsome Therapeutics (AXSM)
August 8, 2023 | msn.com
BofA upgrades Axome to neutral, cites improved outlook for MDD drug
August 8, 2023 | finance.yahoo.com
Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates
August 8, 2023 | finance.yahoo.com
DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls
August 8, 2023 | finance.yahoo.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2023 Earnings Call Transcript
August 8, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Stoke Therapeutics (STOK) and Cassava Sciences (SAVA)
August 8, 2023 | finance.yahoo.com
Q2 2023 Axsome Therapeutics Inc Earnings Call
August 7, 2023 | nasdaq.com
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
See More Headlines
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Company Calendar

Last Earnings
8/07/2023
Today
10/03/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXSM
CUSIP
N/A
CIK
1579428
Web
axsome.com
Phone
(212) 332-3241
Fax
212-320-0245
Employees
422
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$104.45
High Stock Price Forecast
$180.00
Low Stock Price Forecast
$81.00
Forecasted Upside/Downside
+56.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-187,130,000.00
Net Margins
-101.07%
Pretax Margin
-100.00%
Return on Equity
-92.39%
Return on Assets
-36.35%

Debt

Debt-to-Equity Ratio
0.63
Current Ratio
4.52
Quick Ratio
4.44

Sales & Book Value

Annual Sales
$50.04 million
Price / Sales
63.04
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.52 per share
Price / Book
26.53

Miscellaneous

Outstanding Shares
47,190,000
Free Float
35,629,000
Market Cap
$3.15 billion
Optionable
Optionable
Beta
1.91
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Herriot Tabuteau M.D. (Age 55)
    Founder, Chairman, CEO & Pres
    Comp: $1.32M
  • Mr. Nick Pizzie CPAMr. Nick Pizzie CPA (Age 48)
    M.B.A., Chief Financial Officer
    Comp: $732.94k
  • Mr. Mark L. Jacobson (Age 40)
    COO & Sec.
    Comp: $784.66k
  • Mr. Hunter Murdock Esq. (Age 43)
    Gen. Counsel & Sec.
    Comp: $735.39k
  • Dr. Amanda Jones Pharm.D. (Age 40)
    Sr. VP of Clinical Devel.
  • Ms. Lori Englebert M.B.A. (Age 45)
    Exec. VP of Commercial & Bus. Devel.
  • Joseph Debrah-Afful CPA
    M.B.A., Director of Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AXSM Stock - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares.
View AXSM analyst ratings or view top-rated stocks.

What is Axsome Therapeutics' stock price forecast for 2023?

11 Wall Street analysts have issued 1 year price targets for Axsome Therapeutics' shares. Their AXSM share price forecasts range from $81.00 to $180.00. On average, they anticipate the company's share price to reach $104.45 in the next twelve months. This suggests a possible upside of 56.3% from the stock's current price.
View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2023?

Axsome Therapeutics' stock was trading at $77.13 at the beginning of the year. Since then, AXSM shares have decreased by 13.3% and is now trading at $66.85.
View the best growth stocks for 2023 here.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our AXSM earnings forecast.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its earnings results on Monday, August, 7th. The company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.24) by $0.24. The firm earned $46.70 million during the quarter, compared to analyst estimates of $40.19 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 92.39% and a negative net margin of 101.07%.

What ETFs hold Axsome Therapeutics' stock?

ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC).First Trust Nasdaq Pharmaceuticals ETF (FTXH).

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $66.85.

How much money does Axsome Therapeutics make?

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $3.15 billion and generates $50.04 million in revenue each year. The company earns $-187,130,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

The company employs 422 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.

This page (NASDAQ:AXSM) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -